Unjha Formulations Ltd

Thu 3/09/2026,16:1:0 | BSE : UNJHAFOR

₹29.191.39 (5.00%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 29.00

Previous Close

₹ 27.80

Volume

23890

Mkt Cap ( ₹ Cr)

₹ 13.08

High

₹ 29.19

Low

₹ 29.00

52 Week High

₹ 29.50

52 Week Low

₹ 17.52

Book Value Per Share

₹ 8.93

Dividend Yield

₹ 0.00

Face Value

₹₹10.00

What's Your Call?

Collective community sentiment on Unjha Formulations Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Unjha Formulations Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Unjha Formulatio Q1 net profit down 58.97% at Rs 0.16 cr

    17 Aug 2026, 7:00AM The company reported standalone net profit of Rs 0.16 crore for the quarter ended June 30, 2026 as compared to Rs 0.39 crore in the same period last y
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Regulation (30) Of The SEBI (Listing Obligation And Disclosure \r\nRequirements) Regulations,2015 ,Details

    14 Aug 2026, 7:02PM REGULATION 44(3) OF SEBI(LODR) REGULATION ,2015 /\r\nSCRUTINIZER REPORT
  • Unjha Formulatio - Filing Of Distribution Schedule

    14 Aug 2026, 6:44PM As per Regulation of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Cash Flow Statement For The Year Ended 31.03.2026

    14 Aug 2026, 6:39PM Cash Flow Statement for the year ended 31.03.2026
  • Unjha Formulatio - Cash Flow Statement For The Year Ended 31.03.2026

    14 Aug 2026, 6:38PM Cash Flow Statement for the year ended 31.03.2026
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Outcome of AGM

    14 Aug 2026, 11:47AM REGULATION 30 OF THE SEBI (LODR) 2015, OUTCOME OF AGM HELD ON 14-08-2026
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    14 Aug 2026, 7:07PM Regulation 44(3) of SEBI(LODR) Regulation,2015
  • Unjha Formulatio - Publish Audited Financial Results For The Quarter And Year Ended As On 30/06/2026

    5 Aug 2026, 2:29PM REG 33 (3) OF SEBI (LODR) ACT 2015
  • Unjha Formulatio - Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended On 30Th June ,2026 And

    3 Aug 2026, 3:12PM Regulation 33 of SEBI(LODR) Act 2015
  • Unjha Formulatio - Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For First Quarter Ended

    3 Aug 2026, 3:04PM Regulation 33 of the SEBO(LODR) Act 2015
  • Unjha Formulatio - E- Voting Facility At The Forthcoming Annual General Meeting & Intimation Of Fixation Of Cut-Off Date

    28 Jul 2026, 2:06PM Section 108 of companies act , 2013
  • Unjha Formulatio - Regulation 30 & 34(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015,

    20 Jul 2026, 2:36PM Regularion 30 & 34 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015
  • Unjha Formulatio - Reg. 34 (1) Annual Report.

    20 Jul 2026, 2:27PM Regulation 34(1) of SEBI(LODR) Act 2015
  • Unjha Formulatio - Compliance With Regulation 47 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations,201

    20 Jul 2026, 2:05PM Published Notice of AGM in LokMitra (Gujarati) and Free Press (English) non 18/07/2026
  • Unjha Formulatio - Notice Of 32Th Annual General Meeting Of Company To Be Held On 14Th August, 2026 .\r\n\r\n

    16 Jul 2026, 2:02PM NOTICE OF 32TH ANNUAL GENERAL MEETING OF COMPANY
  • Unjha Formulatio - Board Meeting Intimation for Board Meeting - Date: 03.08.2026( Un-Audited Financial Results For The Quarte

    16 Jul 2026, 1:58PM Unjha Formulations Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider a
  • Unjha Formulatio has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    15 Jul 2026, 5:10PM As of June 2026, 36.92% is owned by Indian Promoters and 63.08% by Public. <p align=justify> Top four Promoters holding highest number of shares of Un
  • Unjha Formulatio - Reply To Clarification On Price Movement Sought By BSE Limited

    15 Jul 2026, 3:57PM Reply to clqarification on price movement
  • Unjha Formulatio - Newspaper Advertisement For 32Th Annual General Meeting TO To Be Held On 14Th August,2026

    15 Jul 2026, 3:43PM News papers Advertisement for 32th Annual General Meeting
  • Unjha Formulatio - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    15 Jul 2026, 3:16PM Compliance Certificate under Regu 74(5) of SEBI (DP Regulations
  • Unjha Formulatio - Clarification sought from Unjha Formulations Ltd

    13 Jul 2026, 5:12PM The Exchange has sought clarification from Unjha Formulations Ltd on July 13, 2026 with reference to significant movement in price, in order to ensure
  • Unjha Formulatio - BOOK CLOSURE

    13 Jul 2026, 2:08PM REGULATION 42(2) OF SEBI LODR, REGULATIONS 2015
  • Unjha Formulatio - Intimation Of Book Closure Pursuant To Section 91 Of Companies Act,2013 And Regulation 42 Of The SEBI (Lis

    3 Jul 2026, 2:25PM Regulation 42 of SEBI (LODR) Act 2015
  • Unjha Formulatio - Annual General Meeting To Be Held On 14Th August, 2026

    3 Jul 2026, 2:21PM Annual General Meeting to be held on 14th August,2026
  • Unjha Formulatio - Annual Large Corporate Disclosure

    23 Jun 2026, 3:25PM Annual Large corporate Disclosure 202526

Key fundamentals

Evaluate the intrinsic value of Unjha Formulations Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 3.8434 3.1387 2.7312 2.4534 2.1708
Liabilities 3.8434 3.1387 2.7312 2.4534 2.1708
Equity 4.4805 4.4805 4.4805 4.4805 4.4805
Gross Profit 0.9401 0.5154 0.5758 0.4332 0.3217
Net Profit 0.7047 0.4075 0.2779 0.2824 0.2524
Cash From Operating Activities 1.2438 -0.0449 1.0261 -0.3146 0.2765
NPM(%) 4.52 2.93 1.5 2.14 1.78
Revenue 15.5852 13.8621 18.496 13.1537 14.1639
Expenses 14.6451 13.3467 17.9202 12.7205 13.8422
ROE(%) 17.61 10.18 6.94 7.05 6.31

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Unjha Formulations Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 867.50 -0.74 22.01 15.87 -26.19 0.57
Lotus Eye Hospital and Institute Ltd 110.65 1.47 1561.14 57.81 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 15.31 -1.54 0.00 120.04 -39.50 0.00
Astec Lifesciences Ltd 571.00 -0.23 0.00 61.94 -363.14 0.00

Company Info

M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in

M/s. Unjha Formulations Limited was established in June 1987 as a partnership firm for manufacturing Pharmaceutical Formulations at Khali Char Rasta, Tal: Sidhpur, Dist: Mehsana. The firm has now been converted into a Public Limited Company vide Certificate of Incorporation No.04/22932 of 1994-95 dated 2.9.94. The company is presently manufacturing pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles etc. The Company is one of the largest manufacturers of Isabgul products in India. The company is located in the heart of Isabgul growing region, worldwide. The Company has seen uninterrupted growth since incorporation and the sales have consistently risen from Rs.85 lacs in 1991-92 to Rs.348.50 lacs in 1994-95. The Company is presently manufacturing an extensive range of Pharmaceutical Formulations for human consumption and for veteniary use. The sales therefore are divided into the two segments viz: human consumption and veterinary products. In the proposed expansion programme, the company proposes to manufacture additional tablets and injectibles for human consumption and also catering veterinary market. The company has identified the market segment for veterinary drugs as a less competitive market. Other Companies promoted by the promoter are in the business of procuring and trading in Psyllium husk. The Company procures this processed husk for its various products. Therefore, there is no conflict of interest. Also not all the raw material is procured from companies promoted by the same promoters and procurement is based on best rates available. "Gelax" is one of the main products of the company, catering to the domestic market. The Company has signed a MOU with the Indian Immunological Hyderabad (a unit of the National Dairy Development Board) for the offtake of their products. The Company has seen its exports continuously increase from Rs.5.52 lacs in 1991-92 to Rs.38.56 lacs in 1994-95. The company has received Export Orders from Companies in Kenya, and Dubai for Magnesium Silicate Compound and Isabgul Products, worth Rs.46.10 lacs. The Company is operating in an industry where there are major pharmaceutical companies - both Indian and Multinational - operating. However the company has an inherent advantage in that it is located in the heart of the Isabgul growing regions in the world with promoters well experienced in the procurement of Psyllium Husk - the major raw material for the company's products. Also it has firm marketing tie up with a major concern which has a strong brand image. 2007 E-mail ID for Investor Complaints :unjfor@sancharnet.in

Parent Organisation

Unjha Formulations Ltd.

Founded

02/09/1994

Managing Director

Mrs.Krutiben M Patel

NSE Symbol

FAQ